Compare Moderna, Inc. (MRNA) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs RLX Technology Inc — how do they compare? Moderna, Inc. trades at $137.25 (market cap $56.02B), while RLX Technology Inc trades at $1.77 (market cap $2.19B). The key difference: Moderna, Inc. is far larger — about 25.6× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.59% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | RLX | |
|---|---|---|
Market Cap | $56.02B | $2.19B |
Sector | Health | Technology |
52-Week High | $174.38 | $2.69 |
52-Week Low | $22.36 | $1.76 |
Enterprise Value | $52.17B | $919.18M |
Dividend Yield | — | 5.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
RLX trades at $1.79, down 0.56% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue growth of 14.8% year-over-year, driven by international expansion, though it missed EPS estimates for the third consecutive quarter. Profitability remains solid with a net income margin of 21.87% and a P/E ratio of 16.1, indicating reasonable valuation.
The outlook is mixed; international growth offers opportunity, but consistent earnings misses and a sole 'Hold' analyst rating suggest caution. Key risks include execution in new markets and regulatory scrutiny. The stock lacks bullish momentum but holds fundamental strength if expansion delivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
